Analysts’ Viewpoint
Rise in prevalence of cancer and increase in awareness about early diagnosis of cancer are driving the global AI in cancer diagnostics market. Integration of AI technologies in cancer diagnostics has shown promising results, improving accuracy, efficiency, and patient outcomes. Analysis of large volume of complex data and improved diagnostic accuracy are propelling market expansion. Furthermore, development of personalized treatment strategies using AI algorithms to identify patterns and correlations that guide tailored treatment plans are expected to bolster the global AI in cancer diagnostics market size in the near future.
Initiation of awareness programs by governments to diagnose cancer at an early stage and decrease the mortality rate associated with cancer offers lucrative opportunities to market players. Collaborations between technology companies, healthcare providers, and research institutions are vital for the advancement of AI in cancer diagnostics.
Integration of Artificial Intelligence (AI) in the field of cancer diagnostics marks a leap forward in the quest to enhance early detection, accurate diagnosis, and personalized treatment of cancer. AI, with its ability to analyze massive volumes of complex medical data and extract insights, is revolutionizing the landscape of cancer diagnosis. The need for more efficient, precise, and timely diagnostic solutions in cancer diagnostics requires a fast and reliable method.
Traditional diagnostics methods struggle to keep pace with the growing complexity of cancer research and patient data. AI employs advanced algorithms to process various information ranging from medical images to genomic sequences and clinical records. AI detects and analyzes small irregularities that humans might not notice.
Shortage of skilled medical professionals, especially in areas such as radiology and pathology, has amplified the urgency and need for AI in cancer diagnostics.
Integration of AI in cancer diagnostics represents a transformative shift that can help in early detection, precise diagnosis, and tailored treatment strategies, ultimately leading to improved patient outcome.
Early diagnosis of cancer has a significant impact on reducing the death rate associated with the disease. Early intervention to limit or prevent cancer development and lethality associated with it is made possible by early detection of cancer or precancerous changes. When cancer is diagnosed at an early stage, it is often more treatable, and the chances of successful treatment and long-term survival are higher.
AI algorithms can analyze medical imaging data, such as CT scans, MRI scans, and pathology slides, with high precision and speed. AI can reduce diagnostic errors and ensure early detection. AI powered diagnostic tools analyze vast amount of data in quick time, which helps in quicker diagnosis and enables healthcare professionals to initiate treatment promptly. AI powered cancer diagnostics process ensures consistent and reliable results.
Early diagnosis not only improves patient outcomes, but also contributes to cost saving in healthcare systems by detecting cancer at an early stage. Moreover, transmission of the disease can be minimized and appropriate preventive measures can be implemented.
Therefore, increase in awareness about early diagnosis of cancer is likely to drive global AI in cancer diagnostics market demand in the next few years.
In term of component, the software solutions segment accounted for the largest global AI in cancer diagnostics market share in 2022. AI-powered software is essential for processing and analyzing vast amounts of complex data in cancer diagnostics. Software forms the foundation for developing and deploying machine learning and deep learning algorithms in cancer diagnostics.
Software plays a leading role in AI in cancer diagnostics market growth due to its ability to process & analyze complex data and facilitate machine learning & deep learning algorithms. It helps in integration with existing healthcare systems and provides user-friendly interfaces that allow continuous updates and improvements in the diagnostics process.
Based on cancer type, the breast cancer segment dominated the global AI in cancer diagnostics industry in 2022. Breast cancer is one of the most commonly diagnosed cancers globally, affecting a large number of individuals. According to WHO, around 2.3 million women are diagnosed with breast cancer and 685,000 deaths were recorded globally in 2020. In the past five years, around 7.8 million women were diagnosed with breast cancer.
High incidence and prevalence of breast cancer create a significant need for accurate and efficient diagnostic tools. AI-powered technologies, such as computer-aided detection (CAD) systems, can assist radiologists in analyzing mammograms and other breast imaging modalities, aiding in early detection and diagnosis.
Imaging modalities such as MRI and ultrasound generate a vast amount of data, which can be challenging for healthcare professionals to analyze comprehensively. AI in breast cancer diagnostics has the potential to assist in risk assessment and stratification.
By analyzing patient data, including family history, genetic profiles, and lifestyle factors, AI algorithms can identify individuals at higher risk of developing breast cancer. This information can help healthcare providers formulate personalized screening and prevention strategies, enabling early intervention and reducing the mortality rate associated with breast cancer.
In term of application, the screening & diagnosis segment is projected to account for the largest global AI for cancer diagnostics market share in 2022. Cancer is an aggressive disease with a low median survival rate. Accurate early diagnosis is essential to enhance patient survival rate.
AI models are extremely adept at handling vast amounts of data. Integrative processing and extraction allow investigators more accurate disease diagnosis due to the efficiency and effectiveness of learning.
Based on end-user, the diagnostic centers segment held significant market share in 2022. Diagnostic centers lead the AI in cancer diagnostics market expansion due to their specialized expertise, access to diverse patient data, state-of-the-art imaging equipment, collaborations with AI technology providers, integration with electronic health record systems, centralized diagnostic services, and adherence to quality assurance and accreditation standards.
According to AI in cancer diagnostics market research, North America accounted for significant share of the global market in 2022. This is ascribed to strong foundation in research & development and encouragement for innovation in AI applications for cancer diagnostics in the region.
Advanced healthcare infrastructure, including top-tier medical institutions, research centers, and hospitals, and expertise to adopt & integrate AI technologies into their diagnostic processes are driving demand for AI in cancer diagnostics in North America.
As per AI in cancer diagnostics market trends, Asia Pacific is expected to witness significant market expansion during the forecast period. The region is experiencing rapid increase in the incidence and prevalence of cancer. Rise in cancer burden has created demand for advanced diagnostic tools, including AI in cancer diagnostics, to address the growing healthcare needs. Large population, diverse patient demographics, and increase in awareness about the benefits of early cancer detection contribute to market growth in Asia Pacific.
The AI in cancer diagnostics market report concludes with the company profiles section that includes key information about the major players. Companies focus on strategies such as new product launches, mergers, and partnerships & collaborations to compete in the marketplace.
Microsoft, Mindpeak GmbH, Ibex Medical Analytics, Cancer Center.ai, Path AI, EarlySign, Kheiron Medical Technologies Limited, Whiterabbit.ai, Freenome, Paige AI, Inc., Flatiron, SkinVision, Therapixel, and Tempus are the prominent players in the global market.
Prominent players have been profiled in the AI in cancer diagnostics market report based on parameters such as company overview, financial overview, strategies, portfolio, segments, and recent developments.
| Attribute | Detail |
|---|---|
|
Size in 2022 |
US$ 859.0 Mn |
|
Forecast (Value) in 2031 |
More than US$ 2.0 Bn |
|
Growth Rate (CAGR) |
11.2% |
|
Forecast Period |
2023-2031 |
|
Historical Data Available for |
2017-2021 |
|
Quantitative Units |
US$ Mn/Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
It was valued at US$ 859.0 Mn in 2022.
It is projected to reach more than US$ 2.0 Bn by 2031.
It is anticipated to advance at a CAGR of 11.2% from 2023 to 2031.
Rise in awareness about early diagnosis of cancer and increase in prevalence of cancer globally.
The software solutions component segment accounted for more than 60.0% share in 2022.
North America is expected to account for the largest share from 2023 to 2031.
Microsoft, Mindpeak GmbH, Ibex Medical Analytics, Cancer Center.ai, Path AI, EarlySign, Kheiron Medical Technologies Limited, Whiterabbit.ai, Freenome, Paige AI, Inc., Flatiron, SkinVision, Therapixel, and Tempus.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global AI in Cancer Diagnostics Market
4. Market Overview
4.1. Introduction
4.1.1. Component Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global AI in Cancer Diagnostics Market Analysis and Forecast, 2017-2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Different Technique Overview of Machine Learning in Oncology
5.2. Technological Advancements
5.3. List of Major Software used as AI in Cancer Diagnostics
5.4. Regulatory Scenario by Region/Globally
5.5. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)
6. Global AI in Cancer Diagnostics Market Analysis and Forecast, by Component
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Component, 2017-2031
6.3.1. Software Solutions
6.3.2. Services
6.4. Market Attractiveness Analysis, by Component
7. Global AI in Cancer Diagnostics Market Analysis and Forecast, by Cancer Type
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Cancer Type, 2017-2031
7.3.1. Breast Cancer
7.3.2. Prostate Cancer
7.3.3. Lung Cancer
7.3.4. Colorectal Cancer
7.3.5. Cervical Cancer
7.3.6. Others
7.4. Market Attractiveness Analysis, by Cancer Type
8. Global AI in Cancer Diagnostics Market Analysis and Forecast, by Application
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Application, 2017-2031
8.3.1. Screening & Diagnosis
8.3.2. Tumor Identification
8.3.3. Monitoring
8.4. Market Attractiveness Analysis, by Application
9. Global AI in Cancer Diagnostics Market Analysis and Forecast, by End-user
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast, by End-user, 2017-2031
9.3.1. Hospitals
9.3.2. Diagnostic Centers
9.3.3. Medical Research Institutes
9.3.4. Contract Research Organizations
9.4. Market Attractiveness Analysis, by End-user
10. Global AI in Cancer Diagnostics Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2017-2031
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, by Region
11. North America AI in Cancer Diagnostics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Component, 2017-2031
11.2.1. Software Solutions
11.2.2. Services
11.3. Market Value Forecast, by Cancer Type, 2017-2031
11.3.1. Breast Cancer
11.3.2. Prostate Cancer
11.3.3. Lung Cancer
11.3.4. Colorectal Cancer
11.3.5. Cervical Cancer
11.3.6. Others
11.4. Market Value Forecast, by Application, 2017-2031
11.4.1. Screening & Diagnosis
11.4.2. Tumor Identification
11.4.3. Monitoring
11.5. Market Value Forecast, by End-user, 2017-2031
11.5.1. Hospitals
11.5.2. Diagnostic Centers
11.5.3. Medical Research Institutes
11.5.4. Contract Research Organizations
11.6. Market Value Forecast, by Country, 2017-2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Component
11.7.2. By Cancer Type
11.7.3. By Application
11.7.4. By End-user
11.7.5. By Country
12. Europe AI in Cancer Diagnostics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Component, 2017-2031
12.2.1. Software Solutions
12.2.2. Services
12.3. Market Value Forecast, by Cancer Type, 2017-2031
12.3.1. Breast Cancer
12.3.2. Prostate Cancer
12.3.3. Lung Cancer
12.3.4. Colorectal Cancer
12.3.5. Cervical Cancer
12.3.6. Others
12.4. Market Value Forecast, by Application, 2017-2031
12.4.1. Screening & Diagnosis
12.4.2. Tumor Identification
12.4.3. Monitoring
12.5. Market Value Forecast, by End-user, 2017-2031
12.5.1. Hospitals
12.5.2. Diagnostic Centers
12.5.3. Medical Research Institutes
12.5.4. Contract Research Organizations
12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Italy
12.6.5. Spain
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Component
12.7.2. By Cancer Type
12.7.3. By Application
12.7.4. By End-user
12.7.5. By Country/Sub-region
13. Asia Pacific AI in Cancer Diagnostics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Component, 2017-2031
13.2.1. Software Solutions
13.2.2. Services
13.3. Market Value Forecast, by Cancer Type, 2017-2031
13.3.1. Breast Cancer
13.3.2. Prostate Cancer
13.3.3. Lung Cancer
13.3.4. Colorectal Cancer
13.3.5. Cervical Cancer
13.3.6. Others
13.4. Market Value Forecast, by Application, 2017-2031
13.4.1. Screening & Diagnosis
13.4.2. Tumor Identification
13.4.3. Monitoring
13.5. Market Value Forecast, by End-user, 2017-2031
13.5.1. Hospitals
13.5.2. Diagnostic Centers
13.5.3. Medical Research Institutes
13.5.4. Contract Research Organizations
13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Component
13.7.2. By Cancer Type
13.7.3. By Application
13.7.4. By End-user
13.7.5. By Country/Sub-region
14. Latin America AI in Cancer Diagnostics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Component, 2017-2031
14.2.1. Software Solutions
14.2.2. Services
14.3. Market Value Forecast, by Cancer Type, 2017-2031
14.3.1. Breast Cancer
14.3.2. Prostate Cancer
14.3.3. Lung Cancer
14.3.4. Colorectal Cancer
14.3.5. Cervical Cancer
14.3.6. Others
14.4. Market Value Forecast, by Application, 2017-2031
14.4.1. Screening & Diagnosis
14.4.2. Tumor Identification
14.4.3. Monitoring
14.5. Market Value Forecast, by End-user, 2017-2031
14.5.1. Hospitals
14.5.2. Diagnostic Centers
14.5.3. Medical Research Institutes
14.5.4. Contract Research Organizations
14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Component
14.7.2. By Cancer Type
14.7.3. By Application
14.7.4. By End-user
14.7.5. By Country/Sub-region
15. Middle East & Africa AI in Cancer Diagnostics Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Component, 2017-2031
15.2.1. Software Solutions
15.2.2. Services
15.3. Market Value Forecast, by Cancer Type, 2017-2031
15.3.1. Breast Cancer
15.3.2. Prostate Cancer
15.3.3. Lung Cancer
15.3.4. Colorectal Cancer
15.3.5. Cervical Cancer
15.3.6. Others
15.4. Market Value Forecast, by Application, 2017-2031
15.4.1. Screening & Diagnosis
15.4.2. Tumor Identification
15.4.3. Monitoring
15.5. Market Value Forecast, by End-user, 2017-2031
15.5.1. Hospitals
15.5.2. Diagnostic Centers
15.5.3. Medical Research Institutes
15.5.4. Contract Research Organizations
15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Component
15.7.2. By Cancer Type
15.7.3. By Application
15.7.4. By End-user
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix, by tier and size of companies
16.2. Market Share Analysis, by Company, 2022
16.3. Company Profiles
16.3.1. Ibex Medical Analytics
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. EarlySign
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. Cancer Center.ai
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Microsoft
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Flatiron
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Path AI
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Therapixel
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Tempus
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Paige AI, Inc.
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. Kheiron Medical Technologies Limited
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview
16.3.11. SkinVision
16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.11.2. Product Portfolio
16.3.11.3. Financial Overview
16.3.11.4. SWOT Analysis
16.3.11.5. Strategic Overview
16.3.12. Freenome
16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.12.2. Product Portfolio
16.3.12.3. Financial Overview
16.3.12.4. SWOT Analysis
16.3.12.5. Strategic Overview
16.3.13. Whiterabbit.ai
16.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.13.2. Product Portfolio
16.3.13.3. Financial Overview
16.3.13.4. SWOT Analysis
16.3.13.5. Strategic Overview
16.3.14. Mindpeak GmbH
16.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.14.2. Product Portfolio
16.3.14.3. Financial Overview
16.3.14.4. SWOT Analysis
16.3.14.5. Strategic Overview
List of Tables
Table 01: Global AI in Cancer Diagnostics Market Value (US$ Mn) Forecast, by Component, 2017-2031
Table 02: Global AI in Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017-2031
Table 03: Global AI in Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 04: Global AI in Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 05: Global AI in Cancer Diagnostics Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 06: North America AI in Cancer Diagnostics Market Value (US$ Mn) Forecast, by Component, 2017-2031
Table 07: North America AI in Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017-2031
Table 08: North America AI in Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 09: North America AI in Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 10: North America AI in Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 11: Europe AI in Cancer Diagnostics Market Value (US$ Mn) Forecast, by Component, 2017-2031
Table 12: Europe AI in Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017-2031
Table 13: Europe AI in Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 14: Europe AI in Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 15: Asia Pacific AI in Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 16: Asia Pacific AI in Cancer Diagnostics Market Value (US$ Mn) Forecast, by Component, 2017-2031
Table 17: Asia Pacific AI in Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017-2031
Table 18: Asia Pacific AI in Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 19: Asia Pacific AI in Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 20: Latin America AI in Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 21: Latin America AI in Cancer Diagnostics Market Value (US$ Mn) Forecast, by Component, 2017-2031
Table 22: Latin America AI in Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017-2031
Table 23: Latin America AI in Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 24: Latin America AI in Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 25: Middle East & Africa AI in Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 26: Middle East & Africa AI in Cancer Diagnostics Market Value (US$ Mn) Forecast, by Component, 2017-2031
Table 27: Middle East & Africa AI in Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017-2031
Table 28: Middle East & Africa AI in Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 29: Middle East & Africa AI in Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017-2031
List of Figures
Figure 01: Global AI in Cancer Diagnostics Market Value Share Analysis, by Component, 2022 and 2031
Figure 02: Global AI in Cancer Diagnostics Market Attractiveness Analysis, Component, 2023-2031
Figure 03: Global AI in Cancer Diagnostics Market Value (US$ Mn) Forecast, by Software Solutions, 2017-2031
Figure 04: Global AI in Cancer Diagnostics Market Revenue (US$ Mn), by Services, 2017-2031
Figure 05: Global AI in Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017-2031
Figure 06: Global AI in Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2023-2031
Figure 07: Global AI in Cancer Diagnostics Market Revenue (US$ Mn), by Breast Cancer, 2017-2031
Figure 08: Global AI in Cancer Diagnostics Market Revenue (US$ Mn), by Prostate Cancer, 2017-2031
Figure 09: Global AI in Cancer Diagnostics Market Revenue (US$ Mn), by Lung Cancer, 2017-2031
Figure 10: Global AI in Cancer Diagnostics Market Revenue (US$ Mn), by Colorectal Cancer, 2017-2031
Figure 11: Global AI in Cancer Diagnostics Market Revenue (US$ Mn), by Cervical Cancer, 2017-2031
Figure 12: Global AI in Cancer Diagnostics Market Revenue (US$ Mn), by Others, 2017-2031
Figure 13: Global AI in Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017-2031
Figure 14: Global AI in Cancer Diagnostics Market Attractiveness Analysis, Application, 2023-2031
Figure 15: Global AI in Cancer Diagnostics Market Revenue (US$ Mn), by Screening & Diagnosis, 2017-2031
Figure 16: Global AI in Cancer Diagnostics Market Revenue (US$ Mn), by Tumor Identification, 2017-2031
Figure 17: Global AI in Cancer Diagnostics Market Revenue (US$ Mn), by Monitoring, 2017-2031
Figure 18: Global AI in Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Figure 19: Global AI in Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Figure 20: Global AI in Cancer Diagnostics Market Revenue (US$ Mn), by Hospitals, 2017-2031
Figure 21: Global AI in Cancer Diagnostics Market Revenue (US$ Mn), by Diagnostic Centers, 2017-2031
Figure 22: Global AI in Cancer Diagnostics Market Revenue (US$ Mn), by Medical Research Institutes, 2017-2031
Figure 23: Global AI in Cancer Diagnostics Market Revenue (US$ Mn), by Contract Research Organizations, 2017-2031
Figure 24: Global AI in Cancer Diagnostics Market Value (US$ Mn) Forecast, by Region, 2017-2031
Figure 25: Global AI in Cancer Diagnostics Market Attractiveness Analysis, by Region, 2023-2031
Figure 26: North America AI in Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017-2031
Figure 27: North America AI in Cancer Diagnostics Market Value Share Analysis, by Country, 2022 and 2031
Figure 28: North America AI in Cancer Diagnostics Market Attractiveness Analysis, by Country, 2023-2031
Figure 29: North America AI in Cancer Diagnostics Market Value Share Analysis, by Component, 2022 and 2031
Figure 30: North America AI in Cancer Diagnostics Market Attractiveness Analysis, Component, 2023-2031
Figure 31: North America AI in Cancer Diagnostics Market Value Share Analysis, by Cancer Type, 2022 and 2031
Figure 32: North America AI in Cancer Diagnostics Market Attractiveness Analysis, Cancer Type, 2023-2031
Figure 33: North America AI in Cancer Diagnostics Market Value Share Analysis, by Application, 2022 and 2031
Figure 34: North America AI in Cancer Diagnostics Market Attractiveness Analysis, by Application, 2023-2031
Figure 35: North America AI in Cancer Diagnostics Market Value Share Analysis, by End-user, 2022 and 2031
Figure 36: North America AI in Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2023-2031
Figure 37: Europe AI in Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017-2031
Figure 38: Europe AI in Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 39: Europe AI in Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 40: Europe AI in Cancer Diagnostics Market Value Share Analysis, by Component, 2022 and 2031
Figure 41: Europe AI in Cancer Diagnostics Market Attractiveness Analysis, Component, 2023-2031
Figure 42: Europe AI in Cancer Diagnostics Market Value Share Analysis, by Cancer Type, 2022 and 2031
Figure 43: Europe AI in Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2023-2031
Figure 44: Europe AI in Cancer Diagnostics Market Value Share Analysis, by Application, 2022 and 2031
Figure 45: Europe AI in Cancer Diagnostics Market Attractiveness Analysis, by Application, 2023-2031
Figure 46: Europe AI in Cancer Diagnostics Market Value Share Analysis, by End-user, 2022 and 2031
Figure 47: Europe AI in Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2023-2031
Figure 48: Asia Pacific AI in Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017-2031
Figure 49: Asia Pacific AI in Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 50: Asia Pacific AI in Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 51: Asia Pacific AI in Cancer Diagnostics Market Value Share Analysis, by Component, 2022 and 2031
Figure 52: Asia Pacific AI in Cancer Diagnostics Market Attractiveness Analysis, Component, 2023-2031
Figure 53: Asia Pacific AI in Cancer Diagnostics Market Value Share Analysis, by Cancer Type, 2022 and 2031
Figure 54: Asia Pacific AI in Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2023-2031
Figure 55: Asia Pacific AI in Cancer Diagnostics Market Value Share Analysis, by Application, 2022 and 2031
Figure 56: Asia Pacific AI in Cancer Diagnostics Market Attractiveness Analysis, by Application, 2023-2031
Figure 57: Asia Pacific AI in Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2023-2031
Figure 58: Latin America AI in Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017-2031
Figure 59: Latin America AI in Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 60: Latin America AI in Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 61: Latin America AI in Cancer Diagnostics Market Value Share Analysis, by Component, 2022 and 2031
Figure 62: Latin America AI in Cancer Diagnostics Market Attractiveness Analysis, Component, 2023-2031
Figure 63: Latin America AI in Cancer Diagnostics Market Value Share Analysis, by Cancer Type, 2022 and 2031
Figure 64: Latin America AI in Cancer Diagnostics Market Attractiveness Analysis, Cancer Type, 2023-2031
Figure 65: Latin America AI in Cancer Diagnostics Market Value Share Analysis, by Application, 2022 and 2031
Figure 66: Latin America AI in Cancer Diagnostics Market Attractiveness Analysis, by Application, 2023-2031
Figure 67: Latin America AI in Cancer Diagnostics Market Value Share Analysis, by End-user, 2022 and 2031
Figure 68: Latin America AI in Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2023-2031
Figure 69: Middle East & Africa AI in Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017-2031
Figure 70: Middle East & Africa AI in Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 71: Middle East & Africa AI in Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 72: Middle East & Africa AI in Cancer Diagnostics Market Value Share Analysis, by Component, 2022 and 2031
Figure 73: Middle East & Africa AI in Cancer Diagnostics Market Attractiveness Analysis, Component, 2023-2031
Figure 74: Middle East & Africa AI in Cancer Diagnostics Market Value Share Analysis, by Cancer Type, 2022 and 2031
Figure 75: Middle East & Africa AI in Cancer Diagnostics Market Attractiveness Analysis, Cancer Type, 2023-2031
Figure 76: Middle East & Africa AI in Cancer Diagnostics Market Value Share Analysis, by Application, 2022 and 2031
Figure 77: Middle East & Africa AI in Cancer Diagnostics Market Attractiveness Analysis, by Application, 2023-2031
Figure 78: Middle East & Africa AI in Cancer Diagnostics Market Value Share Analysis, by End-user, 2022 and 2031
Figure 79: Middle East & Africa AI in Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2023-2031
Figure 80: Global AI in Cancer Diagnostics Market Share Analysis, by Company 2022
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
AI in Cancer Diagnostics Market
*86 figures and 60 tables includes